ADVANCE launches public consultation on the ADVANCE Code of Conduct


The Accelerated Development of VAccine benefit-risk Collaboration in Europe (ADVANCE) ( is a public-private partnership supported by the Innovative Medicines Initiative ( in order to establish a scientific and transparent framework for the rapid monitoring of the benefits and risks of marketed vaccines. EMA is contributing to this project by co-leading within WP1 the development of a Good practice guidance with a Code of Conduct for the planning, initiation, design, conduct and reporting of observational studies in the field of vaccines. The Code of Conduct will also support interactions between different parties involved in studies on vaccines and provide confidence to health professionals and the public about the quality of their results. ADVANCE has launched a public consultation of the draft Code of Conduct until 15th November 2015.

Please find here the draft Code of Conduct.

Please use this form to send your comments to within the deadline.